Project: Targets and biomarkers of the novel anticancer compounds inducing oxidative stress in cancer cells

Acronym OxidoCurin (Reference Number: 11481)
Duration 01/08/2017
Project Topic We will further develop the novel anti-cancer lead compound LCTA2290 and its analogs: 1) Experimentally validate the target, identified during the first phase of the project – thioredoxin reductase 1 (TrxR1); 2) Identify the additional target(s) using state-of the-art TPP methodology; 2) Elucidate the mechanism of interaction of lead compound with the target(s) and the mechanism of action; 4) Identify biomarkers of sensitivity and resistance of cancer cells and the mechanism of possible toxicity
Network Eurostars 2
Call Eurostars Cut-Off 7

Project partner

Number Name Role Country
1 geneXplain GmbH Coordinator Germany
2 HDxperts AB Partner Sweden
3 Karolinska Institute Partner Sweden